Regenerative therapy has the potential for transforming healthcare through non-invasive procedures, and has made its way into clinical practice due to recent advances in biomedical science. Instead of targeting symptoms, regenerative therapy attempts to restore the structure and function of damaged tissues and cells from past injuries, chronic conditions, degenerative diseases and more. BioGenix advances this mission with the world's most advanced umbilical cord allograft products.
Cell paracrine actions and tissue regeneration. Baranaki PR & McDevitt TC. Regenerative Medicine. 2010 Jan.
Wang et al. Stem Cells Development. 2013 Dec.
Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson-s disease. Venkataramana NK et al. Translational Research. 2010 Feb.
Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. Perico N et al. Transplant International. 2013 Sep.
This website is intended to inform and educate medical professionals. It is NOT intended for patients. It also does not seek to make claims about the effectiveness of regenerative medicine and its respective therapies in medical treatment.
Regenerative therapies have great potential in helping treat a range of conditions. This site serves to inform medical professionals about regenerative medicine, BioGenix allograft products, and key in vitro, animal model, and clinical research studies that have been carried out to date across medical specialties and health conditions. However, regenerative medicine is an early and evolving field, and clinical studies are still insufficient to determine effectiveness.
While the BioGenix products are produced in an FDA compliant laboratory, it has not been approved by the FDA for treatment effectiveness. The FDA states:
Like other medical products that are intended to treat, cure or prevent disease, generally require FDA approval before they can be marketed. FDA has not approved any stem cell-based products for use, other than cord blood-derived hematopoietic progenitor cells (blood-forming stem cells) for certain indications.
Patients interested in regenerative therapy in the U.S. are advised to consult a physician about the state of FDA approval for any given product and/or inquire about opportunities to participate in a clinical trial. Patients interested in regenerative therapies outside the U.S. should investigate regulations in the specific country. It is important to be aware that regulations and clinical study requirements vary from country to country.
By clicking yes you confirm that you are a medical professional, understand that the information contained in this website is intended for medical professionals and not for the general public, and have read and understood the disclaimer above.